{
    "clinical_study": {
        "@rank": "51856", 
        "acronym": "Nilo Post-STIM", 
        "arm_group": {
            "arm_group_label": "Nilotinib", 
            "arm_group_type": "Experimental", 
            "description": "300 mg/twice a day"
        }, 
        "brief_summary": {
            "textblock": "Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal\n      translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth\n      and survival of leukemic cells. In the past decade, the bcr-abl tyrosine kinase inhibitor\n      (TKI) imatinib (IM or Glivec\u00a9) has been the standard of care for patients with CML, inducing\n      durable responses. However, requiring continuing IM indefinitely and the ability of IM to\n      eradicate the CML clone was uncertain.\n\n      In a small proportion of patients, IM can induce complete molecular response (CMR) defined\n      by the disappearance of the bcr-abl transcript in conventional quantitative RT-PCR. The\n      question whether or not these patients are cured and can discontinue drug therapy has been\n      assessed by Mahon and coll, in the STIM study. He demonstrates that IM can be safely\n      discontinued in patient with a CMR of at least 2 year duration and all patients who relapsed\n      after IM discontinuation mainly did it in the first 6 months and responded to reintroduction\n      of imatinib.\n\n      Nilotinib is a rationally designed second generation tyrosine kinase inhibitor with improved\n      target specificity over imatinib. Its efficacy and safety in the treatment of patients who\n      are resistant or intolerant to imatinib as well as patients with newly diagnosed CML-CP led\n      to the registration in second and first line treatment of CML-CP patients. Nilotinib\n      produces even faster and deeper responses with more occurrence of CMR than does Imatinib.\n      Consequently, one can assume that a more potent drug such nilotinib could induce deeper and\n      sustained CMR allowing longer period off treatment than IM.\n\n      The objective of this pilot trial is to assess if Nilotinib can rescue STIM patients in\n      molecular relapse after IM discontinuation and to provide an estimation about duration of\n      CMR after nilotinib discontinuation in 2nd line therapy among patients experiencing 2 years\n      of stable CMR with nilotinib."
        }, 
        "brief_title": "Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with CML included in STIM trials, stopped their treatment by imatinib because the\n      signal was not detectable. In case of reappearance of this transcript Bcr-Abl, the patient\n      relapses. The trial Nilo Post STIM is suggested to the patient to assess if Nilotinib can\n      rescue STIM patients in molecular relapse after IM discontinuation and to provide an\n      estimation about duration of CMR after nilotinib discontinuation in 2nd line therapy among\n      patients experiencing 2 years of stable CMR with nilotinib.\n\n      The treatment/strategy for this study:\n\n        -  Screening\n\n             -  Inclusion/exclusion criteria\n\n             -  CML history\n\n             -  Confirm molecular relapse after discontinuation of imatinib (quantitative RT-PCR\n                on two consecutive assessments from peripheral blood samples)\n\n        -  Treatment\n\n           \u2022 Nilotinib 300mg BID  for 2 years\n\n             -  Premature treatment discontinuation while on study: primary or secondary\n                resistance   progression to accelerated phase or blast crisis, AE (to be defined\n                later).\n\n             -  In case of unsatisfactory response:  transcript stability or increase on two\n                consecutive PCR: nilotinib blood monitoring,   and nilotinib dose escalation up to\n                400mg BID will be proposed\n\n             -  Discontinuation at 2 years for patients who resumed confirmed CMR\n\n        -  Follow-up while on treatment with nilotinib:\n\n             -  Physical exam, basic laboratory parameters, monthly during the first 3 months then\n                every 3 months.\n\n             -  Centralized quantitative RT-PCR for Bcr-Abl monthly for 6 months then every 3\n                months for 24 months\n\n             -  Follow AE management guidelines for nilotinib reduction/interruptions\n\n        -  Follow-up after nilotinib discontinuation\n\n             -  Patients in confirmed molecular relapse\n\n                  -  Physical exam, event collection, basic laboratory parameters (including\n                     glycemic and lipid profile) every 2 months during the first year then every 3\n                     months\n\n                  -  Hematology  and centralized quantitative RT-PCR monthly the first year then\n                     every 3 months for 12 months\n\n             -  Patients without confirmed molecular relapse will take another treatment\n                (dasatinib for example) and will stop their follow-up in the trial"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients\n\n          -  Patient participating to the STIM trials (including STIM, STIM2 et EURO-SKI)  and\n             with confirmed molecular relapse on two consecutive RQ PCR, after imatinib\n             discontinuation\n\n          -  Still in chronic phase\n\n          -  Not yet treated for this relapse\n\n          -  At least 18 years old (no upper age limit)\n\n          -  SGOT and SGPT < 2.5 UNL\n\n          -  Serum creatinin < 2 UNL\n\n          -  No planned allogeneic stem cell transplantation\n\n          -  Signed informed consent\n\n          -  ECOG score 0 to 2\n\n        Exclusion Criteria:\n\n          -  Pregnancy, lactation\n\n          -  Prior or concurrent malignancy other than CML (exceptions to be mentioned)\n\n          -  Serious uncontrolled cardiovascular disease\n\n          -  Severe psychiatric/neurological disease (previous or ongoing)\n\n          -  Ongoing treatment at risk for inducing \"torsades de pointe\"\n\n          -  QTcF > 450ms despite correction of predisposing factors (i.e electrolytes\u2026)\n\n          -  Congenital long QTcF\n\n          -  No health insurance coverage"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774630", 
            "org_study_id": "CHUBX 2012/18"
        }, 
        "intervention": {
            "arm_group_label": "Nilotinib", 
            "description": "300 mg/twice a day", 
            "intervention_name": "Nilotinib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Treatment, relapse, complete molecular response", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Martine GARDEMBAS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49033"
                    }, 
                    "name": "CHU Angers"
                }, 
                "investigator": {
                    "last_name": "Martine GARDEMBAS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "G.Etienne@bordeaux.unicancer.fr", 
                    "last_name": "Gabriel ETIENNE, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "investigator": [
                    {
                        "last_name": "Gabriel ETIENNE, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Josy REIFFERS, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fran\u00e7ois-Xavier MAHON, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anna SCHMITT, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Marc BERGER, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont- Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }, 
                    "name": "Chu Estaing"
                }, 
                "investigator": {
                    "last_name": "Marc BERGER, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "prousselot@ch-versailles.fr", 
                    "last_name": "Philippe ROUSSELOT, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Chesnay", 
                        "country": "France", 
                        "zip": "78157"
                    }, 
                    "name": "Centre Hospitalier de Versailles - H\u00f4pital Andr\u00e9 Mignot - Service de M\u00e9decine B"
                }, 
                "investigator": {
                    "last_name": "Philippe ROUSSELOT, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mp-noel@chru-lille.fr", 
                    "last_name": "Marie-Pierre NOEL, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "H\u00f4pital Claude Huriez, Service des Maladies du Sang"
                }, 
                "investigator": [
                    {
                        "last_name": "Marie-Pierre NOEL, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Val\u00e9rie COITEUX, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie CAMBIER, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "charbonniera@marseille.fnclcc.fr", 
                    "last_name": "Aude CHARBONNIER, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Institut Paoli Calmette, Service H\u00e9matologie 3"
                }, 
                "investigator": [
                    {
                        "last_name": "Aude CHARBONNIER, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Norbert VEY, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thomas PREBET, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jer\u00f4me REY, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne ETIENNE, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Evelyne D'INCAN, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "viviane.dubruille@chu-nantes.fr", 
                    "last_name": "Viviane DUBRUILLE, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44035"
                    }, 
                    "name": "CHU H\u00f4tel Dieu, Service d'H\u00e9mato-Canc\u00e9rologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Viviane DUBRUILLE, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "B\u00e9atrice MAHE, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "CLAVERT Aline, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nicolas BLIN, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "legros.l@chu-nice.fr", 
                    "last_name": "Laurence LEGROS, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06202"
                    }, 
                    "name": "CHU de Nice, Service H\u00e9matologie Clinique"
                }, 
                "investigator": [
                    {
                        "last_name": "Laurence LEGROS, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jean-Michel KARSENTI, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.rousselot@chu-stlouis.fr", 
                    "last_name": "Philippe ROUSSELOT, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint Louis, Service des Maladies du Sang"
                }, 
                "investigator": [
                    {
                        "last_name": "Philippe ROUSSELOT, Pr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Delphine REA, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bruno.varet@nck.aphp.fr", 
                    "last_name": "Bruno VARET, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }, 
                    "name": "H\u00f4pital Necker-Enfants Malades, Service d'H\u00e9matologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Bruno VARET, Pr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Agn\u00e8s BUZYN, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Felipe SUAREZ, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Francois-Xavier.Mahon@umr5540.u-bordeaux2.fr", 
                    "last_name": "Fran\u00e7ois-Xavier MAHON, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "H\u00f4pital Haut L\u00e9v\u00eaque, Service H\u00e9matologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Fran\u00e7ois-Xavier MAHON, Pr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "G\u00e9rald MARIT, Pr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.nicolini@chu-lyon.fr", 
                    "last_name": "Franck NICOLINI, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Centre Hospitalier Lyon Sud, Service H\u00e9matologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Franck NICOLINI, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mauricette MICHALLET, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xavier THOMAS, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fiorenza BARACCO, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "H\u00e9l\u00e8ne LABUSSIERE, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie DETRAIT, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Youcef CHELGHOUM, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie DUCASTELLE, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fran\u00e7ois GUILHOT, Md, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France", 
                        "zip": "86021"
                    }, 
                    "name": "CHRU de Poitiers"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7ois GUILHOT, Md, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "pconymakhoul@ch-annecy.fr", 
                    "last_name": "Pascale CONY-MAKHOUL, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Pringy", 
                        "country": "France", 
                        "zip": "74374"
                    }, 
                    "name": "CH d'Annecy"
                }, 
                "investigator": [
                    {
                        "last_name": "Pascale CONY-MAKHOUL, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bernadette CORRONT, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "martine.escoffre-barbe@chu-rennes.fr", 
                    "last_name": "Martine ESCOFFRE-BARBE, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "H\u00f4pital Pontchaillou"
                }, 
                "investigator": [
                    {
                        "last_name": "Martine ESCOFFRE-BARBE, Dr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bernard Marc, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Charles DAURIAC, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Stanislas NIMUBONA, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xavier CAHU, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thierry LAMY DE LA CHAPELLE, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Roch HOUOT, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie DE GUIBERT, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "huguet.f@chu-toulouse.fr", 
                    "last_name": "Fran\u00e7oise RIGAL-HUGUET, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU de Toulouse, Service d'H\u00e9matologie"
                }, 
                "investigator": [
                    {
                        "last_name": "Lucie OBERIC, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Guy LAURENT, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Christian RECHER, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne HUYNH, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lo\u00efc YSEBAERT, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fran\u00e7oise RIGAL-HUGUET, Dr", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Emmanuel GYAN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "CHU de Tours"
                }, 
                "investigator": {
                    "last_name": "Emmanuel GYAN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jixing LIU, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Valence", 
                        "country": "France", 
                        "zip": "26953"
                    }, 
                    "name": "CH Valence"
                }, 
                "investigator": {
                    "last_name": "Jixing LIU, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "a.guerci@chu-nancy.fr", 
                    "last_name": "Agn\u00e8s-Paule GUERCI, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54500"
                    }, 
                    "name": "CHU Brabois, Service de M\u00e9decine A"
                }, 
                "investigator": {
                    "last_name": "Ang\u00e8s-Paule GUERCI, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)", 
        "overall_contact": {
            "email": "Francois-xavier.mahon@umr5540.u-bordeaux2.fr", 
            "last_name": "Fran\u00e7ois-Xavier MAHON, MD PhD", 
            "phone": "+ 33 5 57 65 65 11"
        }, 
        "overall_official": [
            {
                "affiliation": "Nantes University Hospital", 
                "last_name": "Viviane DUBRUILLE", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Hospital Bordeaux, France", 
                "last_name": "Gabriel ETIENNE", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Hospital Lyon", 
                "last_name": "Franck NICOLINI", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "APHP, St Louis Hospital", 
                "last_name": "Delphine REA", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Ministry of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CMR is defined as >5 log reduction in Bcr-Abl and Abl levels and undetectable transcripts on quantitative RTq-PCR", 
            "measure": "Estimated survival rate of patients without molecular relapse 3 years after enrollment", 
            "safety_issue": "Yes", 
            "time_frame": "Evaluation by RTq-PCR monthly the first year of treatment with nilotinib then every 3 months until 24 months, date of discontinuation of Nilotinib for patients in sustained complete molecular response (CMR). After discontinuation of Nilotinib patie"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Same definition of CMR as above", 
                "measure": "Rate and kinetics of CMR while on treatment with nilotinib", 
                "safety_issue": "Yes", 
                "time_frame": "at 6 and 12 months of treatment with nilotinib"
            }, 
            {
                "description": "Defined as the time from the date of first documented CMR to the date of first confirmed molecular relapse defined as positivity of Bcr-Abl transcripts in quantitative RT-PCR with a ratio of bcr-abl to Abl \u2265 10-5, as confirmed by a second analysis point at two successive assessments", 
                "measure": "Duration of CMR while on treatment with nilotinib", 
                "safety_issue": "Yes", 
                "time_frame": "Any time"
            }, 
            {
                "description": "Events include loss of major molecular response (MMR) , loss of complete cytogenetic response (CCyR) loss of complete hematologic response (CHR), progression to accelerated phase and blst crisis (AP-BC), death whatever the cause, adverse-event leading to premature discontinuation of nilotinib", 
                "measure": "Event free survival (EFS)", 
                "safety_issue": "Yes", 
                "time_frame": "Any time"
            }, 
            {
                "description": "Haematological and non-haematological adverse events (AE) graded will be according to the NCI CTC AE v4. Compliance will be estimated using the 4 items Morisky scale", 
                "measure": "Safety tolerability of nilotinib and compliance", 
                "safety_issue": "Yes", 
                "time_frame": "Any time"
            }, 
            {
                "measure": "Duration of CMR after nilotinib discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Measured from the start of nilotinib discontinuation to the date of first confirmed molecular relapse as defined above"
            }, 
            {
                "description": "Same events as for EFS described above", 
                "measure": "Event free survival (EFS)", 
                "safety_issue": "Yes", 
                "time_frame": "Overall and after nilotinib discontinuation"
            }, 
            {
                "description": "Parameters will be recorded before and after both sequences of treatment  imatinib and nilotinib", 
                "measure": "Predictive factors of maintained CMR after nilotinib discontinuation: sex, Sokal risk score at diagnosis, duration of previous treatment with imatinib, CMR duration before and after discontinuation of imatinib", 
                "safety_issue": "Yes", 
                "time_frame": "After discontinuation of nilotinib"
            }
        ], 
        "source": "University Hospital, Bordeaux", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Bordeaux", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}